Market news

RxSight (RXST) has upside potential if it executes salesforce expansion and utilization-growth initi

Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

RxSight (RXST) has an average rating of hold and mean price target of $7.57, according to analysts p

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]

Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. Second Quarter 2026 Highlights Total company Q2 revenue of $33.7 million, which includes $6.5 million in revenue recognized from the RxSight Alcon strategic collaborationQ2 product sales of $27.2 million including: 24,917 Light Adjustable Lens (LAL) units;12 Light Delivery Devices (LDD) unit

RxSight (NASDAQ:RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the b

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RxSight (RXST) has an average rating of hold and mean price target of $8.06, according to analysts p

ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight’s common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight’s common stock to Aziz Mottiwala, RxSight’s new President and Chief Executive Officer in connection with his commencement of employment with RxSight. The inducement stock options

RxSight’s latest valuation work has taken the modelled fair value from US$9.93 to US$8.43, which points to a refreshed view of what the stock may be worth under updated assumptions. Analysts are linking this reset to softer recent Q2 trends, revised guidance, and the timing of potential contributions from the new Alcon collaboration. As you read on, you will see how these moving parts are shaping the evolving RxSight story and what to watch next in the analyst narrative. Stay updated as the...

RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.

RxSight (NASDAQ:RXST) reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustab

Alcon (SWX:ALC) shares are in focus after the company agreed a non exclusive collaboration with RxSight to co develop adjustable presbyopia correcting intraocular lenses for cataract patients seeking more tailored visual outcomes. See our latest analysis for Alcon. At a share price of CHF54.0, Alcon has seen short term share price support, with a 1 month share price return of 1.39%, but the 90 day share price return is down 11.48% and the 1 year total shareholder return is down 20.92%. This...

The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.

GENEVA, July 06, 2026--Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses. Preliminary Second Quarter 2026 Results Total company revenue is expected to be approximately $32 to $34 million, whi